Participated · Series A · Aug 2022

HanchorBio is a biotechnology company focused on immuno-oncology that develops proprietary Fc-based designer biologics (FBDB™) with multi-targeting modalities. Founded in December 2020, the company operates out of Taipei, Shanghai, and San Francisco and is led by industry veterans experienced in biologics discovery and global development. Its FBDB™ platform aims to reactivate innate and adaptive immune systems to kill tumors through multifunctional molecular configurations. HanchorBio reported promising in-vivo data from multiple tumor animal models across several projects. The company intends to use new financing to advance its growing pipeline, support IND-enabling GLP toxicology studies and IND submissions, and fund the first part of Phase 1 clinical trials. Management emphasizes improvements in R&D methodologies and CMC process development to translate novel biologics into transformative therapies.

Participated · Series A · Dec 2017

Aldwx.com operates a statistics and ecosystem service platform dedicated to WeChat mini-programs, offering a developer/researcher analytics product, an ecosystem monitor, a third-party developer platform, and a promotion tool. The startup plans to use its new funding to upgrade products, hardware and technologies, and to scale market share and its team. It closed a Series A that valued the company at as much as RMB 1 billion post-funding. The company was founded in 2016 and focuses on servicing the WeChat mini-program ecosystem in China. No operating metrics (revenue/users) are disclosed in the article. Aldwx.com operates a data statistics and developer services platform focused on the WeChat Mini Programs ecosystem. Its products include rankings, a third-party data platform and Xiaoshentui, a fan-interaction tool to help developers monetize Mini Programs. The company says its developers cover 60% of the current top 1,000 Mini Programs and it serves over 100,000 customers, including individual developers, enterprises and organizations. Management is using the fundraising to enrich product lines, expand into new markets, buy servers, cover bandwidth costs, and recruit talent. Aldwx.com plans to begin planning a new product in December and will focus development efforts to reduce operating costs and increase developers' revenue in 2018. The founder, Shi Wenlu, decided to start Aldwx.com when WeChat opened the Mini Programs closed beta on September 21, 2016, and the company positioned itself early as an ecosystem service provider.

Led · Series B · Mar 2010

OriGene Technologies develops and markets biotechnology products and biological reagents for research laboratories, diagnostic companies, clinics and hospitals. Its product portfolio includes cDNA, proteins and antibodies and it provides technological solutions for in‑vitro diagnostics and immunohistochemistry. The company serves both research and clinical diagnostic markets. OriGene plans to use the recent funding to deepen cooperation with global laboratories and to grow product sales in Europe. Founded in 1996 by Weiwu He, the company is based in Rockville, Maryland. The article does not report operating metrics or detailed financials. OriGene Technologies is a Rockville, MD–based genome wide product company that develops, manufactures and sells research and diagnostic products worldwide. Led by Wei-Wu He, Ph.D., Chairman and Chief Executive Officer, the company has developed an array of ultra-specific monoclonal antibodies called UltraMAB™, validated by its proprietary high-density microarray technology for a wide variety of applications. OriGene markets these products for research and diagnostic use globally. The company completed a $21.3M Series C financing to support its business. It intends to use the proceeds to advance its growth strategy and operations. OriGene Technologies is a Rockville, MD-based life sciences company supporting academic institutions and pharmaceutical and biotech companies in research of gene functions and drug discovery. Its core product effort is the TrueMAB™ monoclonal antibody collection. The company is building a collection intended to cover the entire human genome of approximately 20,000 genes. OriGene completed a $16m Series B financing to fund that buildout. The round was led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO, with participation from previous investors Morningside Venture Investments and President International Development Corp. (PIDC). The proceeds will enable OriGene to continue expanding the TrueMAB collection.